Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against KBR, Inc. related to alleged violations of federal securities laws, urging affected investors to contact them before the November 18, 2025 deadline for lead plaintiff applications in a federal class action lawsuit [1][3]. Group 1: Allegations Against KBR - The complaint alleges that KBR and its executives made false or misleading statements regarding the HomeSafe partnership, despite knowing about the U.S. Department of Defense's concerns about HomeSafe's ability to fulfill the Global Household Goods Contract [3]. - The lawsuit claims that KBR's statements about its business operations and prospects were materially false and misleading, leading to investor damages when the true information became public [3]. Group 2: Stock Price Impact - Following the announcement of the termination of the Global Household Goods Contract by HomeSafe on June 19, 2025, KBR's stock price fell by $3.85 per share, or 7.29%, closing at $48.93 on June 20, 2025 [4]. - On the next trading day, KBR's stock experienced an additional decline of $1.30, or 2.65%, closing at $47.63 on June 23, 2025 [4]. Group 3: Legal Process and Participation - The lead plaintiff in the class action is defined as the investor with the largest financial interest who is typical of class members and oversees the litigation on behalf of the class [5]. - Any member of the putative class can apply to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [5].

Core Insights - Hormel Foods Corporation is under investigation for possible violations of federal securities laws, as announced by Levi & Korsinsky [1] - Hormel Foods has cut its earnings forecast due to price pressures, bird flu, and a fire at its Arkansas peanut butter production facility, leading to a stock decline of over 9% on October 29, 2025 [2] Company Overview - Hormel Foods Corporation is facing significant challenges impacting its financial performance, including external pressures from market conditions and operational disruptions [2] - The company has recently parted ways with its Chief Financial Officer, indicating potential internal management issues [2] Legal Context - Levi & Korsinsky LLP, a recognized securities litigation firm, has initiated an investigation into Hormel Foods, highlighting the firm's history of securing substantial settlements for shareholders [3]

Core Viewpoint - A class action lawsuit has been filed against KBR, Inc. for allegedly making false and misleading statements regarding its partnership with the U.S. Department of Defense's Transportation Command, leading to investor losses during the specified Class Period [3][7]. Allegation Details - The lawsuit claims that KBR was aware of concerns from TRANSCOM about HomeSafe's ability to fulfill its Global Household Goods Contract for months but failed to disclose this information [3]. - KBR allegedly misled investors by asserting that its partnership with TRANSCOM would continue to grow despite these concerns [3]. - The company's public statements throughout the Class Period are claimed to be false and materially misleading, resulting in damages to investors when the truth was revealed [3]. Next Steps - Investors who purchased KBR shares between May 6, 2025, and June 19, 2025, and suffered losses are encouraged to contact the law firm for more information and to discuss their rights [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is November 18, 2025 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across the United States [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Molina Healthcare, Inc. due to alleged violations of federal securities laws, encouraging investors who suffered losses exceeding $75,000 to contact them directly [1][3]. Summary by Sections Legal Investigation - The law firm is looking into claims against Molina Healthcare, highlighting a deadline of December 2, 2025, for investors to seek the role of lead plaintiff in a federal securities class action [1][6]. Allegations Against Molina - The complaint alleges that Molina and its executives made false or misleading statements regarding: 1. Material adverse facts about the company's medical cost trend assumptions [3]. 2. A dislocation between premium rates and medical cost trends [3]. 3. Molina's near-term growth being dependent on low utilization of various health services [3]. 4. A substantial likelihood of cutting financial guidance for fiscal year 2025 [3]. 5. Misleading positive statements about the company's business and prospects [3]. Financial Performance and Stock Impact - On July 7, 2025, Molina announced second-quarter financial results, revealing adjusted earnings of approximately $5.50 per share, which was below prior expectations, leading to a 10.2% cut in full-year earnings guidance from at least $24.50 to a range of $21.50 to $22.50 per share [4]. - Following this announcement, Molina's stock price fell by $6.97, or 2.9%, closing at $232.61 per share on July 7, 2025 [4]. - On July 23, 2025, Molina further slashed its full-year earnings guidance, reporting GAAP net income of $4.75 per diluted share for the second quarter, an 8% decrease year-over-year, and cutting full-year adjusted earnings guidance to no less than $19.00 per diluted share, representing a 13.6% cut [5]. - This led to a significant drop in Molina's stock price by $32.03, or 16.84%, closing at $158.22 per share on July 24, 2025 [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Avantor, Inc. due to allegations of misleading statements regarding the company's competitive positioning and financial performance, which have led to significant investor losses [2][3]. Group 1: Allegations and Misleading Statements - The complaint alleges that Avantor and its executives violated federal securities laws by making false and misleading statements about the company's competitive positioning and failing to disclose the negative impacts of increased competition [3]. - During an earnings call on July 26, 2024, the then-CEO Michael Stubblefield assured investors of Avantor's strong competitive position, despite evidence to the contrary [4]. Group 2: Financial Performance and Stock Price Impact - On April 25, 2025, Avantor reported disappointing Q1 2025 results, cutting its guidance and announcing the CEO's resignation, which led to a stock price decline of over 16.5% [5]. - The company continued to report weak financial results, including a net loss of $712 million in Q3 2025, attributed to competitive pressures, resulting in a further stock price drop of over 23% [7][8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Quanex Building Products Corporation due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by November 18, 2025 [4][10]. Group 1: Allegations Against Quanex - The complaint alleges that Quanex and its executives made false or misleading statements and failed to disclose significant underinvestment in tooling and equipment maintenance at its Tyman Mexico facility [6]. - It is claimed that the conditions of tooling and equipment had degraded to near catastrophic levels, leading to significant costs and delays in expected benefits from the Tyman integration [6]. - The complaint also states that Quanex had previously identified these issues, which rendered the company's positive statements about its business and operations materially misleading [6]. Group 2: Financial Impact - On September 4, 2025, Quanex reported a diluted EPS of ($6.04), a significant decline from $0.77 in the same period the previous year, and an adjusted EBITDA of $70.30 [7]. - The company disclosed ongoing operational issues related to the Tyman business that impacted results more than expected during the third quarter of 2025 [7]. - During an earnings call on September 5, 2025, CEO George Wilson noted that operational challenges negatively impacted EBITDA in the Hardware Solutions segment by almost $5 million in the third quarter alone [8]. Group 3: Stock Price Reaction - Following the announcement of poor financial results, Quanex's stock price fell by $2.73, or 13.1%, closing at $18.18 per share on September 5, 2025, with unusually heavy trading volume [8]. - The stock continued to decline, dropping an additional $1.98, or 10.9%, to close at $16.20 per share on September 8, 2025, also on unusually heavy trading volume [9].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Molina Healthcare, Inc. due to allegations of violations of federal securities laws related to misleading statements and undisclosed adverse facts affecting the company's financial performance [4][6]. Summary by Sections Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Molina to contact them regarding their legal options, particularly for those who purchased securities between February 5, 2025, and July 23, 2025 [1][4]. Allegations Against Molina - The complaint alleges that Molina and its executives made false or misleading statements and failed to disclose critical information, including: - Material adverse facts regarding the company's medical cost trend assumptions [6]. - A dislocation between premium rates and medical costs [6]. - Dependency on low utilization of various health services for near-term growth [6]. - Likelihood of a significant cut in financial guidance for fiscal year 2025 [6]. - Misleading positive statements about the company's business and prospects [6]. Financial Performance and Stock Impact - On July 7, 2025, Molina announced second-quarter financial results, revealing adjusted earnings of approximately $5.50 per share, which was below prior expectations, leading to a 10.2% cut in full-year earnings guidance from at least $24.50 to a range of $21.50 to $22.50 per share [7]. - Following this announcement, Molina's stock price fell by $6.97, or 2.9%, closing at $232.61 per share on July 7, 2025 [7]. - On July 23, 2025, Molina further reduced its full-year earnings guidance, reporting GAAP net income of $4.75 per diluted share for the second quarter, an 8% decrease year-over-year, and cutting its full-year adjusted earnings expectation to no less than $19.00 per diluted share, representing a 13.6% reduction [8][9]. - This led to a significant drop in Molina's stock price by $32.03, or 16.84%, closing at $158.22 per share on July 24, 2025 [9].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against V.F. Corporation (VFC) due to allegations of misleading statements regarding the company's turnaround plans and the performance of its Vans brand, which has seen a significant decline in revenue growth [3][5][6]. Group 1: Legal Investigation - The law firm is reminding investors of the November 12, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against VFC [3]. - The firm encourages investors who suffered losses in VFC to contact them directly to discuss their legal options [1][8]. Group 2: Allegations Against VFC - The complaint alleges that VFC and its executives violated federal securities laws by making false or misleading statements about the company's turnaround plans and the necessary actions to return the Vans brand to growth [5]. - The decline in Vans' growth trajectory was highlighted in VFC's fiscal 2025 results, showing a drop from an 8% loss to a 20% loss in the fourth quarter, with expectations of continued decline [6]. Group 3: Market Reaction - Following the revelation of the poor performance and guidance, VFC's stock price fell from $14.43 per share on May 20, 2025, to $12.15 per share on May 21, 2025, marking a decline of approximately 15.8% in one day [6].

Core Viewpoint - A new class action lawsuit has been filed against aTyr Pharma, Inc. and its executives, expanding the alleged class period for investors who suffered losses from November 7, 2024, to September 12, 2025, due to misleading statements about the drug Efzofitimod [1][2][5]. Group 1: Class Action Details - The lawsuit, King v. aTyr Pharma Inc., seeks to represent all individuals and entities that acquired aTyr Pharma securities during the expanded class period [2]. - The previous class period began in January 2025, making this expansion significant for investors who purchased shares in late 2024 [2]. - The lead plaintiff deadline for the lawsuit is set for December 8, 2025 [5]. Group 2: Allegations Against aTyr Pharma - The allegations center around aTyr's Phase 3 study, EFZO-FIT, which evaluated the drug Efzofitimod for patients with pulmonary sarcoidosis [6]. - Executives allegedly made overly positive statements about the study's design and the drug's efficacy, particularly regarding its ability to reduce steroid dependency [7]. - The lawsuit claims that aTyr concealed material adverse facts about the drug's effectiveness, leading to securities law violations [8]. Group 3: Market Reaction and Investigation - The truth about the drug's efficacy was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, resulting in a significant stock price drop from $6.03 to $1.02, an 83.2% decline [9][10]. - Hagens Berman is investigating whether aTyr misled investors regarding the drug's data and trial design while promoting its multi-billion-dollar market potential [11].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Jasper Therapeutics, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and lack of proper manufacturing controls [2][4]. Group 1: Legal Investigation - The firm is encouraging investors who suffered losses exceeding $75,000 in Jasper between November 30, 2023, and July 3, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Jasper, with a deadline of November 18, 2025, for investors to seek the role of lead plaintiff [2][6]. Group 2: Allegations Against Jasper - The complaint alleges that Jasper lacked necessary controls to ensure third-party manufacturers complied with current Good Manufacturing Practices (cGMP), which could confound study results and negatively impact product prospects [4]. - Specific issues were highlighted regarding the BEACON Study, where results were confounded by a problematic drug product lot, leading to a halt in development for certain studies and a need for cost-cutting measures [5]. Group 3: Financial Impact - Following the announcement of these issues, Jasper's stock price fell by $3.73 per share, or 55.1%, closing at $3.04 per share on July 7, 2025 [5].